This $2.5 billion investment reflects AstraZeneca's belief in "the world-class life sciences ecosystem in Beijing" and its ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

China's commitment to foster innovation and advance high-standard opening-up has provided global pharmaceutical companies ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

尽管科五上市的Biotech在现阶段依然面临盈利难的问题，但在高强度研发加码下，科五上市公司未来有望进一步推动更多创新产品、疗法问世，在不远的将来，相信可以看到科五公司从现阶段的惠及患者延伸到未来的惠及股东。

Beijing is keen to woo foreign investment amid heightened geopolitical tensions, as policymakers try to boost domestic ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

March 14, 2025 — China’s recent breakthroughs in AI have captured global attention, but a quieter revolution is unfolding in biotech. Once known primarily for generics and contract manufacturing, ...

The pharmaceutical company said the investment in the research-and-development center in Beijing will bolster its footprint ...

BEIJING -- China will work to further stabilize foreign investment in 2025, implementing measures to open up more fields and ...

Hyderabad: As global trade wars rage on, sending countries and companies scrambling to de-risk their global supply chains, ...